SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

KUVAN

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since December 2007.
Why 3/10
KUVAN is an already-approved, marketed drug with no pending regulatory decision or pivotal readout. It contributes only about 2% of BioMarin's total revenue and is in decline due to generic competition. No hard, dated binary catalyst exists for this drug in the next 12 months, so the impact score is capped at 3-5 per the rubric, and the declining commercial trajectory justifies the lower end of that range.
Actionable Insight NEUTRAL

KUVAN has no upcoming regulatory catalysts or pivotal readouts; it is a mature, declining product facing generic erosion. For BioMarin investors, the focus should remain on VOXZOGO's growth trajectory, the integration of the Amicus acquisition (GALAFOLD, POMBILITI+OPFOLDA), and the PDUFA target action date of May 30, 2027 for VOXZOGO in hypochondroplasia. KUVAN itself is not a stock-moving catalyst.

Price Chart

Loading chart...

Executive Summary

KUVAN (sapropterin dihydrochloride) is an FDA-approved oral therapy for phenylketonuria (PKU), a rare genetic disorder. BioMarin launched it in 2007 as the first specific drug for PKU. The drug is now in late lifecycle: generic competition entered in 2023, and KUVAN revenue has been steadily declining. In Q3 2026, KUVAN contributed just $23 million to BioMarin's $1.025 billion in total quarterly revenue (roughly 2% of sales), down 4% year over year. The drug faces multiple generic competitors and is no longer a meaningful growth driver for BioMarin, which has shifted focus to VOXZOGO, GALAFOLD, and other pipeline assets.

How It Works

KUVAN is a synthetic version of a naturally occurring body chemical called tetrahydrobiopterin (BH4). In some people with PKU, the enzyme that breaks down the amino acid phenylalanine is partially dysfunctional. KUVAN acts as a "chaperone" that helps this enzyme work better, lowering phenylalanine levels in the blood. It is taken orally as a tablet or powder dissolved in liquid, alongside a phenylalanine-restricted diet.

Trial Status

KUVAN was approved by the FDA in December 2007 for phenylketonuria (PKU) and has been commercially marketed since then. No active pivotal clinical trials are ongoing for KUVAN; it is a mature, approved product.

The Two-Sided Case

▲ Bull Case3
KUVAN was the first FDA-approved drug for PKU and remains a recognized brand with established prescribing patterns among metabolic disease specialists.
BioMarin continues to support KUVAN with patient access programs, and the drug still generates positive cash flow even with generic competition.
The latest FDA-listed patent extends to May 2033, providing some theoretical long-tail exclusivity protection for certain formulations.
▼ Bear Case4
Generic competition is well-established: Camber Pharmaceuticals launched a generic in January 2023, and there are now 8 approved generic makers in the FDA Orange Book, eroding KUVAN's market share and pricing power.
KUVAN revenue is in structural decline: Q3 2026 revenue was $23 million (down 4% YoY), and full-year 2025 KUVAN sales declined 18% due to generic pressure.
KUVAN now represents only about 2% of BioMarin's total quarterly revenue, making it immaterial to the company's overall financial performance and investment thesis.
No new indications, label expansions, or formulation upgrades are in development, so the revenue decline is likely to continue.

Upcoming Catalysts

  • None for KUVAN specifically. For BioMarin overall: Q4 2026 earnings (early 2027), PDUFA target action date of May 30, 2027 for VOXZOGO in hypochondroplasia.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 10

Hover a chip for the title
1 drugs.com2 biomarin.com3 camberpharma.com4 drugs.com5 biomarin.com6 sec.gov7 zacks.com8 drugpatentwatch.com9 rivvi.ai10 biomarin.com